NVO trades 17.0% below Wall Street's consensus target of $44.67.
Last 12 months price action with 12-month analyst target path
The base valuation assumes NVO achieves its forward estimates and maintains a stable P/E multiple of 1.7x. This scenario reflects the blended consensus of 39 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Novo Nordisk A/S (NVO) has a Wall Street consensus price target of $44.67, based on estimates from 39 covering analysts. With the stock currently trading at $38.17, this represents a potential upside of +17.0%. The company has a market capitalization of $169.50B.
Analyst price targets range from a low of $40.00 to a high of $47.00, representing a 16% spread in expectations. The median target of $47.00 differs from the mean, suggesting potential outlier estimates. The tight target dispersion indicates high conviction among analysts.
The current analyst consensus rating is Buy, with 23 analysts rating the stock as a Buy or Strong Buy,13 rating it Hold, and 3 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, NVO trades at a trailing P/E of 10.9x and forward P/E of 1.7x. The forward PEG ratio of 0.08 suggests the stock may be undervalued relative to its growth. Analysts expect EPS to grow -14.8% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $335.48, with bear and bull scenarios of $211.35 and $442.03 respectively. Model confidence stands at 63/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 LLYEli Lilly and Company | $1.1T | $1152.70 | $1343.07 | +16.5% | Buy | 31.7x | 45 |
 SNYSanofi | $100.0B | $41.66 | $49.50 | +18.8% | Hold | 10.0x | 27 |
 AZNAstraZeneca PLC | $126.6B | $163.33 | $186.67 | +14.3% | Buy | 15.9x | 41 |
 NVSNovartis AG | $271.3B | $142.71 | $153.00 | +7.2% | Hold | 16.2x | 25 |
 ROGRogers Corporation | $2.5B | $139.44 | $150.00 | +7.6% | Buy | 38.2x | 12 |
 MRKMerck & Co., Inc. | $365.8B | $148.11 | $158.12 | +6.8% | Buy | 53.9x | 38 |
 PFEPfizer Inc. | $160.6B | $28.17 | $28.50 | +1.2% | Hold | 9.5x | 39 |
 BMYBristol-Myers Squibb Company | $124.9B | $61.15 | $70.00 | +14.5% | Buy | 8.8x | 42 |
 ABBVAbbVie Inc. | $468.7B | $265.30 | $287.08 | +8.2% | Buy | 18.9x | 43 |
 JNJJohnson & Johnson | $648.0B | $269.17 | $286.93 | +6.6% | Buy | 23.4x | 40 |
Quick answers to the most common questions about buying NVO stock.
Novo Nordisk A/S (NVO) has a consensus 12-month price target of $44.67, implying 17.0% upside from $38.17. The 39 analysts covering NVO see moderate appreciation potential.
NVO has a consensus rating of "Buy" based on 39 Wall Street analysts. The rating breakdown is predominantly bullish, with 23 Buy/Strong Buy ratings. The consensus 12-month price target of $44.67 implies 17.0% upside from current levels.
With a forward P/E of 1.7071x, NVO trades at a relatively low valuation. The consensus target of $44.67 implies 17.0% appreciation, suggesting meaningful undervaluation.
The most bullish Wall Street analyst has a price target of $47 for NVO, while the most conservative target is $40. The consensus of $44.67 represents the median expectation. Our quantitative valuation model projects a bull case target of $442 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
NVO is heavily covered by Wall Street, with 39 analysts providing price targets and ratings. Of these, 1 have Strong Buy ratings, 22 have Buy ratings, 13 recommend Hold, and 3 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month NVO stock forecast based on 39 Wall Street analysts shows a consensus price target of $44.67, with estimates ranging from $40 (bear case) to $47 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $335, with bear/bull scenarios of $211/$442.
Our quantitative valuation model calculates NVO's fair value at $335 (base case), with a bear case of $211 and bull case of $442. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 63/100.
NVO trades at a forward P/E ratio of 1.7x based on next-twelve-months earnings estimates compared to a trailing P/E of 10.9x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are optimistic on NVO, with a "Buy" consensus rating and $44.67 price target (17.0% upside). 23 of 39 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
NVO analyst price targets range from $40 to $47, a 16% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $44.67 consensus represents the middle ground. Our model's $211-$442 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
Bull/bear thesis, analyst target revisions, and earnings execution.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.